# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA2060037 | F | Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay | Homo sapiens | 41 | cell-based format | Scientific Literature | ||
2. | ALA2060038 | F | Agonist activity at human GPR109a expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP production by HTRF assay relative to 100 uM niacin | Homo sapiens | 33 | cell-based format | Scientific Literature | ||
3. | ALA2060039 | F | Agonist activity at human GPR109b assessed as decrease in forskolin-stimulated cAMP production by HTRF assay | Homo sapiens | 39 | assay format | Scientific Literature | ||
4. | ALA2060040 | A | Activity at CYP2D6 | Homo sapiens | 2 | single protein format | Scientific Literature | ||
5. | ALA2060041 | A | Activity at CYP2C8 | Homo sapiens | 2 | single protein format | Scientific Literature | ||
6. | ALA2060042 | A | Activity at CYP2C9 | Homo sapiens | 2 | single protein format | Scientific Literature | ||
7. | ALA2060043 | A | Activity at CYP3A4 | Homo sapiens | 2 | single protein format | Scientific Literature | ||
8. | ALA2060044 | A | Time dependent inhibition of CYP3A4 at 10 and 50 uM | Homo sapiens | 2 | single protein format | Scientific Literature | ||
9. | ALA2060045 | F | Antidyslipedic activity in fasted Sprague-Dawley rat assessed as decrease in free fatty acid level at 0.01 to 100 mg/kg, po by NEFA C-free fatty acid assay | Rattus norvegicus | 2 | organism-based format | Scientific Literature | ||
10. | ALA2060046 | F | Antidyslipedic activity in fasted Sprague-Dawley rat assessed as decrease in free fatty acid level at 0.001 mg/kg, po by NEFA C-free fatty acid assay | Rattus norvegicus | 2 | organism-based format | Scientific Literature | ||
11. | ALA2060047 | F | Antidyslipedic activity in fasted Sprague-Dawley rat assessed as decrease in free fatty acid level at 0.1 to 30 mg/kg, po by NEFA C-free fatty acid assay | Rattus norvegicus | 2 | organism-based format | Scientific Literature | ||
12. | ALA2060048 | T | Toxicity in C57/Bl6 mouse assessed as increase in cutaneous blood flow in ear at 100 mg/kg, ip after 5 mins relative to vehicle treated control by laser doppler flowmetry | Mus musculus | 3 | organism-based format | Scientific Literature | ||
13. | ALA2060049 | A | Blood clearance in mouse | Mus musculus | 2 | organism-based format | Scientific Literature | ||
14. | ALA2060050 | A | Volume of distribution in mouse | Mus musculus | 2 | organism-based format | Scientific Literature | ||
15. | ALA2060051 | A | Terminal half life in mouse | Mus musculus | 2 | organism-based format | Scientific Literature | ||
16. | ALA2060052 | A | Dose normalized Cmax in po dosed mouse | Mus musculus | 2 | organism-based format | Scientific Literature | ||
17. | ALA2060053 | A | Dose normalized AUC in po dosed mouse | Mus musculus | 2 | organism-based format | Scientific Literature | ||
18. | ALA2060054 | A | Oral bioavailability in mouse | Mus musculus | 2 | organism-based format | Scientific Literature | ||
19. | ALA2060055 | A | Plasma clearance in Sprague-Dawley rat at 2 mg/kg, iv | Rattus norvegicus | 2 | organism-based format | Scientific Literature | ||
20. | ALA2060056 | A | Volume of distribution in Sprague-Dawley rat at 2 mg/kg, iv | Rattus norvegicus | 2 | organism-based format | Scientific Literature |